Influence of mannose receptor ubiquitination and TLR signaling on antigen translocation from endosomes into the cytoplasm for cross-presentation

甘露糖受体泛素化和 TLR 信号传导对抗原从内体易位到细胞质进行交叉呈递的影响

基本信息

项目摘要

For cross-presentation, antigens need to be transported from an endosomal compartment into the cytoplasm, a process that is only partially understood. In a first phase of this grant application, we demonstrated that poly-ubiquitination of the Mannose Receptor (MR), an endocytic receptor that targets its ligands specifically towards cross-presentation, is required for such antigen transport. Poly-ubiquitination of the MR mediated the recruitment of p97, an enzyme that provided the energy for antigen translocation, towards the endosomal membrane. Additionally, we identified TSG101 as a dominant negative inhibitor of MR poly-ubiquitination, p97 recruitment and antigen translocation into the cytosol, and hence as an important regulator of cross-presentation. Previous work by our group demonstrated that, after antigen transport into the cytoplasm and proteasomal degradation, antigenderived peptides are translocated by endosomal TAP into the same endosomes, where loading onto MHC I molecules occurs. Such spatial separation compared to MHC I presentation in the ER implies the use of a distinct set of proteasomes in direct proximity to such endosomes. Since p97 during dislocation at the ER recruits proteasomes towards the ER membrane, we would like to investigate in the second part of this proposal whether p97 mediates the recruitment of proteasome subunits also at the endosomal membrane and whether such recruitment is essential for cross-presentation.
对于交叉呈递,抗原需要从内体隔室运输到细胞质,这一过程只有部分了解。在这项赠款申请的第一阶段,我们证明了甘露糖受体(MR)的多泛素化是这种抗原运输所必需的,MR是一种内吞受体,专门针对其配体进行交叉呈递。MR的多泛素化介导了p97的募集,p97是一种为抗原转位提供能量的酶,它向内膜募集。此外,我们发现TSG101是MR多泛素化、p97募集和抗原转位到胞浆的主要负抑制因子,因此是交叉递呈的重要调节因子。本课题组以前的工作表明,在抗原转运到细胞质和蛋白酶体降解后,抗原源性多肽通过内体TAP转移到相同的内体,在那里发生MHC I分子的装载。与内质网中MHC I的呈现相比,这种空间分离意味着在这些内体附近使用了一组不同的蛋白酶体。由于p97在内质网错位的过程中向内质网招募蛋白酶体,我们想在本提案的第二部分探讨p97是否介导蛋白酶体亚单位也在内质体膜上的招募,以及这种招募是否对交叉呈现是必要的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Sven Burgdorf其他文献

Professor Dr. Sven Burgdorf的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

基于细胞工厂的靶向人源硫酸化O-GalNAc/Mannose多糖组的扩增制备
  • 批准号:
    22307020
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
Ferritin-Mannose纳米粒通过糖代谢影响乳腺癌放疗敏感性及其机制研究
  • 批准号:
    82073355
  • 批准年份:
    2020
  • 资助金额:
    57 万元
  • 项目类别:
    面上项目
靶向结核杆菌细胞壁ManLAM的多肽型显像剂,用于鉴别诊断结核病灶与肿瘤病灶的实验研究
  • 批准号:
    30970859
  • 批准年份:
    2009
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目

相似海外基金

Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
The impact of alcohol-induced ATF6-mediated ER stress and Golgi disorganization on pro-metastatic glycosylation of integrins in prostate cancer
酒精诱导的 ATF6 介导的 ER 应激和高尔基体解体对前列腺癌整合素促转移糖基化的影响
  • 批准号:
    10826211
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema
衰变加速因子 (CD55) 可防止香烟烟雾引起的肺气肿中凝集素途径介导的 AT2 细胞功能障碍
  • 批准号:
    10737359
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
CD206 TAM 的治疗靶向增强转移性去势抵抗性前列腺癌的适应性和先天抗肿瘤免疫反应
  • 批准号:
    10731906
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain
通过将 VGF 输送至大脑来治疗阿尔茨海默病的治疗策略
  • 批准号:
    10738951
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Developing imaging nanoprobes to advance prognosis of kidney fibrosis
开发成像纳米探针以改善肾纤维化的预后
  • 批准号:
    10574964
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting immune dysfunction during transition from AKI to CKD
针对 AKI 向 CKD 过渡期间的免疫功能障碍
  • 批准号:
    10636189
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Optimization of protective antibodies response against bacterial adhesins
针对细菌粘附素的保护性抗体反应的优化
  • 批准号:
    10731509
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Role of CREG1 in metabolic homeostasis
CREG1 在代谢稳态中的作用
  • 批准号:
    10608346
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
PLA2R1 Loss-of-Function: A Monogenic Cause of Sarcoidosis in African-Americans in the ACCESS Cohort
PLA2R1 功能丧失:ACCESS 队列中非裔美国人结节病的单基因原因
  • 批准号:
    10651396
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了